Last reviewed · How we verify
standard-dose HHT
At a glance
| Generic name | standard-dose HHT |
|---|---|
| Sponsor | Ascentage Pharma Group Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML (PHASE2)
- Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS (PHASE1, PHASE2)
- Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (PHASE1, PHASE2)
- Ultra-low-dose Chest CT for HHT
- Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia (NA)
- Intranasal Bevacizumab for HHT-Related Epistaxis (PHASE4)
- AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard-dose HHT CI brief — competitive landscape report
- standard-dose HHT updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI